Skip to main content
CRA Foundation Contact Us
Clinical Guidelines CRA Annual Scientific Meeting
0
News & Events
Members
Clinical Resources & Tools
Education & Career Advancements
Research & Grants
About Us
Clinical Guidelines CRA Annual Scientific Meeting
CRA Foundation Contact Us

Search Results

53 Results for:

Search
Clear Search
Refine Results
Displaying: 21-30 of 53 Results
Sort by
Canadian Rheumatology Association Position Statement on Hydroxychloroquine Monitoring Guidance for Optical Coherence Tomography
The antimalarial drugs, hydroxychloroquine (HCQ) and rarely chloroquine, are essential drugs in the treatment of rheumatic diseases. HCQ is currently the only anti-malarial drug available in Canada for the treatment of rheumatic diseases...
Dec 01, 2025
CRA Position Statement on Quebec’s Bill 2 : Protecting Rheumatology Care and Physician Well-being
The Canadian Rheumatology Association (CRA) strongly opposes Bill 2, recently enacted by the Government of Quebec. This legislation introduces coercive measures that undermine physicians’ rights, destabilize the health care system, and threaten the quality of care for patients living with […]
Nov 05, 2025
CRA/CanRIO guidelines for the management of baseline immunosuppression in individuals with pre-existing rheumatic diseases initiating immune checkpoint inhibitors
This living guideline offers up-to-date guidance on the management of baseline immunosuppression (IS) for pre-existing rheumatic diseases (PRDs) when initiating cancer immunotherapy with immune checkpoint inhibitors (ICIs). Split into 2 parts, this guideline provides contemporary baseline IS recommendations for individuals […]
Sep 01, 2025
Abstracts Presented in 2025
Abstracts Presented at the CRA Annual Scientific Meeting in Calgary, Alberta, February 26-March 1, 2025
Jul 24, 2025
Canadian Rheumatology Association Guidelines Handbook
This document is a guide to developing documents containing clinical guidance for the Canadian Rheumatology Association (CRA). It outlines the procedures required to receive CRA endorsement and the recommended overall approach for development. It is not meant to be a […]
Jun 23, 2025
Canadian Rheumatology Association Guidance for Developing & Endorsing Quality Measures to Support Learning Health Systems
The Canadian healthcare system is a complex patchwork of thirteen provincial and territorial systems for delivery of health services, alongside federal responsibility for a limited suite of health services...
Jun 23, 2025
Canadian Rheumatology Association Position Statement for Access to JAK Inhibitors for Children in Canada
JAK inhibitors (JAKi) are an effective treatment for several rheumatic conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA)...
Mar 25, 2025
CRA Position Statement on Safety of Hydroxychloroquine in the Treatment of Rheumatic Diseases
The antimalarial drugs, chloroquine and especially hydroxychloroquine (HCQ), are essential drugs in the treatment of rheumatic diseases...
Mar 23, 2025
Abstracts Presented in 2024
Abstracts Presented at the CRA Annual Scientific Meeting in Winnipeg, Manitoba, February 28-March 2, 2024
Jul 24, 2024
Canadian Rheumatology Association Position Statement on Biologic Access
Biologic medications have become a cornerstone of the treatment for rheumatic diseases in adults and children in Canada. As more biologic options become available, including biosimilars, the ability of patients to access different biologic agents or switch between different formulations […]
Jun 27, 2024